![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role...
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor...
WALTHAM, Mass, May 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0396 | -0.154679645174 | 25.6013 | 25.6013 | 25.4257 | 167 | 25.4257 | SP |
4 | 0.0446 | 0.174784752186 | 25.5171 | 25.78 | 25.4257 | 481 | 25.61693399 | SP |
12 | 0.5017 | 2.00199521149 | 25.06 | 25.78 | 24.9683 | 1586 | 25.30924415 | SP |
26 | 0.5017 | 2.00199521149 | 25.06 | 25.78 | 24.9683 | 1586 | 25.30924415 | SP |
52 | 0.5017 | 2.00199521149 | 25.06 | 25.78 | 24.9683 | 1586 | 25.30924415 | SP |
156 | 0.5017 | 2.00199521149 | 25.06 | 25.78 | 24.9683 | 1586 | 25.30924415 | SP |
260 | 0.5017 | 2.00199521149 | 25.06 | 25.78 | 24.9683 | 1586 | 25.30924415 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions